SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

Size: px
Start display at page:

Download "SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery"

Transcription

1 Section Sub-section Policy Policy# Pharmacy SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Pyxis MedStation Controlled Substances Page 11 of 5 Programmatic Policy and Procedure Effective: 9/12/2018 Version: 1.0 Last New Policy Revised: Da~ ~2~~-z~~-1~ ~~ Pharmacist-in Charge Approval Supersedes: New policy Morgan Peterson, PharmD Date 1hte11 f' Audit 9/12/2021 Date: 1. PURPOSE/SCOPE 1.1. To provide standards and procedures for the safe inventory, management and administration of controlled substances stored in Pyxis MedStation systems at Santa Barbara County Department of Behavioral Wellness (hereafter the "Department") sites This policy applies to all Santa Barbara County Mental Health Services Pharmacy (hereafter the "Pharmacy") staff, Department program staff, and any other persons acting on behalf of the Department who utilize a Pyxis MedStation at their assigned site. 2. DEFINITIONS 2.1. Pyxis MedStation - an automated dispensing system that performs the storage, dispensing, and distribution of medications Schedule II, 111-V controlled substances - a classification of drugs as defined by the United States Controlled Substances Act that have a high potential for abuse and may lead to physical and psychological dependence. Schedules can be found online: usc/812.htm 2.3. Discrepancy - when the inventory count of a controlled substance does not match the count expected by the Pyxis MedStation. There are many causes of medication discrepancies. For example, a discrepancy could occur when a user: 1. Removes a quantity greater or less than the quantity requested. 2. Cancels the removal, but removed the medication from the Pyxis MedStation. 3. Does not remove the medication requested. 4. Makes a typographical error (for example, 11 instead of 1 ).

2 PH ARM Pyxis MedStation Controlled Substances Page J 2 of 5 5. Accesses the wrong pocket during removal, return, refilling or loading. 6. Enters incorrect quantity during re stock or reload. 7. Diverts or pilfers a medication Blind Count - when a user of the Pyxis MedStation system physically counts the inventory of that medication prior to removing that medication from the bin. In a blind count, the system does not display the count, so the user will not know whether they are witnessing a discrepancy Verified Count - in this type of count, the Pyxis MedStation system will display the expected count on the screen. Staff will then confirm this count or will make note of any discrepancy. 3. POLICY 3.1. Medications classified by the Drug Enforcement Administration (DEA) as Schedule II, 111-V controlled substances shall be subject to special management, oversight and accountability. In accordance with all relevant federal and state laws and regulations as well as standards of clinical and pharmacy practice, Department sites utilizing Pyxis MedStation systems to manage controlled substances shall enforce strict controls in the access, storage, return, record-keeping and disposal of controlled substances. 4. CONTROLLED SUBSTANCE COUNTS AND COUNT VERIFICATIONS 4.1. Before a controlled substance can be withdrawn from the Pyxis MedStation for administration to a patient, the doses must be subjected to a blind count. 1. Each time a controlled substance storage location is accessed, the user will be prompted to enter a blind count. The user will count the medication and enter the physical count they record. 2. If the user enters a quantity that is different from the count that the system expects, a discrepancy will be recorded and must be resolved by the end of the shift. Users may still administer controlled substances prior to resolving the discrepancy. 3. The respective program supervisor or manager will monitor completion of the blind counts to ensure this activity is being performed Each week, a verified count on all controlled substances will be performed. The verified count must be completed by a pharmacist and either one (1) licensed nursing staff (LNS) or one (1) other Pharmacy staff (e.g., pharmacist, pharmacy technician). The pharmacist will print a report documenting the verified count. Verified count reports will be stored onsite or at the pharmacy for a minimum of three (3) years Pharmacy staff will maintain an ongoing record of discrepancies or unusual access associated with controlled substances.

3 PHARM Pyxis Med Station Controlled Substances Page 13 of No end-of-shift count is required for controlled substances stored in the Pyxis MedStation except in the event of a system downtime period. Please see the Pyxis MedStation Downtime policy for further information. 5. NEW DISCREPANCIES 5.1. In the event of a discrepancy, an alert will appear on the Pyxis MedStation screen. During the course of the shift, the person discovering the discrepancy is responsible for resolving the discrepancy. 1. If the person who discovers the discrepancy is not an LNS at that site (for example, if they are Pharmacy staff) and they were not involved in the creation of the discrepancy, the discrepancy will be referred to the team lead or program supervisor. 2. If the Pharmacy was involved in the creation of the discrepancy, the team lead, program supervisor or responsible staff will contact the Pharmacy during regular Pharmacy hours to resolve the discrepancy. If a discrepancy is discovered after regular business hours, the Pharmacy will be notified the next business day To obtain information on the persons and medication involved in the discrepancy, staff may review either the Discrepancy Report or Activity Report Resolution of each discrepancy will be documented and witnessed by a second person who may be an LNS and/or Pharmacy staff. 6. UNRESOLVED DISCREPANCIES 6.1. The team lead or designee will check the Pyxis MedStation display for an unresolved discrepancy indicator at the end of each shift If a discrepancy remains unresolved, the user will indicate "Unresolved - follow-up required" on the Pyxis MedStation Discrepancies that cannot be resolved, and/or those discrepancies that have impacted patient care such as resulting in a delay in treatment, will be immediately reported to the on-site supervisor (or, if after hours, the on-call administrator) and an incident report 1 will be completed. 7. CONTROLLED SUBSTANCE RETURNS 7.1. Controlled substances removed from the Pyxis Med Station but not administered to the patient are returned to the bin designated specifically for returned controlled substances. A second LNS is required as a witness when returning controlled medications. 1 Please refer to the Department's "Unusual Occurrence Incident Reporting" policy for further details. For Psychiatric Health Facility (PHF) incident reports, refer to the PHF "Unusual Occurrence Reporting" policy.

4 PHARM : Pyxis MedStation Controlled Substances Page 14 of When a pharmacist verifies the accuracy of controlled substance returns when the designated return bin is emptied, a LNS or Pharmacy staff must serve as a second witness. Once the controlled substances have been verified, they can be placed back into the Pyxis MedStation inventory or sent back to the Pharmacy. 8. DOCUMENTATION AND REPORTING 8.1. All confirmed losses of controlled substances must be reported to the Department of Health Care Services (DHCS) and the California State Board of Pharmacy The Narcotic and Controlled Substances Discrepancy Resolution Report (ORR) will be generated and reviewed on a weekly basis by the Pharmacist-in-Charge or designee. 1. Discrepancy reports must be retained by the Pharmacy for a minimum of three (3) years. ASSISTANCE Morgan Peterson, PharmD, Pharmacist-in-Charge REFERENCES Pyxis Med Station TM 4000 System - Console User Guide (November 2010) California Business and Professions Code Section California Health and Safety Code Section (c)(d)(1) RELATED POLICIES Pyxis MedStation Downtime Pyxis MedStation Medication Storage, Inventory and Restocking Pyxis MedStation Medication Removal and Return Pyxis MedStation Medication Disposal Unusual Occurrence Incident Reporting PHF only- Unusual Occurrence Reporting

5 PHARM : Pyxis Med Station Controlled Substances Page 15 of 5 REVISION RECORD DATE VERSION REVISION DESCRIPTION Culturally and Linguistically Competent Policies The Department of Behavioral Wellness is committed to the tenets of cultural competency and understands that culturally and linguistically appropriate services are respectful of and responsive to the health beliefs, practices and needs of diverse individuals. All policies and procedures are intended to reflect the integration of diversity and cultural literacy throughout the Department. To the fullest extent possible, information, services and treatments will be provided (in verbal and/or written form) in the individual's preferred language or mode of communication (i.e. assistive devices for blind/deaf).

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery

SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Page 1 of 9 SANTA BARBARA COUNTY DEPARTMENT OF Behavioral Wellness A System of Care and Recovery Departmental Polley and Procedure Section Sub-section Alcohol and Drug Program (ADP) Effective: 7/11/2018

More information

Guideline for the Rational Use of Controlled Drugs

Guideline for the Rational Use of Controlled Drugs Guideline for the Rational Use of Controlled Drugs Ministry of Health Male' Republic of Maldives April 2000 Table of Contents Page Introduction.. 2 1. Procurement and Supply of Controlled Drugs 3 1.1 Import

More information

Pyxis MedStation System. Guide for Managing Patient-Specific Medication

Pyxis MedStation System. Guide for Managing Patient-Specific Medication Pyxis MedStation System Guide for Managing Patient-Specific Medication April 2012 CareFusion, Pyxis, Pyxis MedStation, and the CareFusion logo are trademarks or registered trademarks of CareFusion Corporation

More information

SECTION PRESCRIPTIONS

SECTION PRESCRIPTIONS SECTION.1800 - PRESCRIPTIONS 21 NCAC 46.1801 EXERCISE OF PROFESSIONAL JUDGMENT IN FILLING PRESCRIPTIONS (a) A pharmacist or device and medical equipment dispenser shall have a right to refuse to fill or

More information

Chapter 18 Advanced Life Support (ALS) Controlled Substances March 2009

Chapter 18 Advanced Life Support (ALS) Controlled Substances March 2009 Division 05 Emergency Medical March 2009 POLICY This General Order establishes procedures, as mandated by the Comprehensive Drug Abuse Prevention and Control Act of 1970 (Controlled Substances Act), to

More information

Hazardous Materials Medication Box and Exchange Procedure

Hazardous Materials Medication Box and Exchange Procedure May 2017 Page 1 of 5 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material

More information

Drug Diversion and Safe Injections: Risks, Recommendations, & Resources. Oregon Public Health Division Healthcare-Associated Infections HAI Program

Drug Diversion and Safe Injections: Risks, Recommendations, & Resources. Oregon Public Health Division Healthcare-Associated Infections HAI Program Drug Diversion and Safe Injections: Risks, Recommendations, & Resources Oregon Public Health Division Healthcare-Associated Infections HAI Program Drug diversion can lead to infection Hepatitis C virus

More information

Hazardous Materials Medication Box and Exchange Procedure

Hazardous Materials Medication Box and Exchange Procedure September 2012 Page 1 of 6 Hazardous Materials Medication Box and Exchange Procedure EMS Service Stock 1. Each EMS Agency will be responsible for the security and storage of the supply of hazardous material

More information

Do not open the test booklet prior to being told to do so.

Do not open the test booklet prior to being told to do so. Last Name: Pharmacy 431 Pharmacy Ethics and Law Quiz 5 Do not open the test booklet prior to being told to do so. I, the undersigned student, agree to do my best on the exam and that I have only used resources

More information

Dispensing and administration of emergency opioid antagonist without a

Dispensing and administration of emergency opioid antagonist without a 68-7-23. Dispensing and administration of emergency opioid antagonist without a prescription. (a) A pharmacist may dispense an FDA-approved emergency opioid antagonist and the necessary medical supplies

More information

Crowe Healthcare Webinar Series

Crowe Healthcare Webinar Series Crowe Healthcare Webinar Series Healthcare Providers Ongoing Challenges With Controlled Substances Presented by: Scott Gerard, Healthcare Risk Consulting Partner Eric Jolly, Healthcare Risk Vice President

More information

North Dakota Board of Pharmacy

North Dakota Board of Pharmacy North Dakota Board of Pharmacy Updates on Drug Abuse Trends, the PDMP and Medical Marijuana Mark J. Hardy, Pharm D Executive Director Disclosure Statement I have no conflict of interests to report Objectives

More information

UNIVERSITY POLICY. Revised: Contact:

UNIVERSITY POLICY. Revised: Contact: UNIVERSITY POLICY Policy Name: Policy for Controlled Substances Section #: 90.2.3 Section Title: Compliance Approval Authority: Responsible Executive: Responsible Office: Formerly Book: President Adopted:

More information

Prescription Drug Monitoring Program

Prescription Drug Monitoring Program California Department of Justice Prescription Drug Monitoring Program May, 2016 Health and Safety Code section 11165. (a) To assist health care practitioners in their efforts to ensure appropriate prescribing,

More information

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015.

Louisiana. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Louisiana Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Student Number. PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999

Student Number. PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999 PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION 2 November 10, 1999 Questions 1-25 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions

More information

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System

Controlled Substance Prescribing: A Physician s Guide. Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Controlled Substance Prescribing: A Physician s Guide Bethanie Gamble, PharmD Department of Pharmacy Greenville Health System Objectives Review schedules of controlled substances and their propensity for

More information

PYXIS MEDSTATION EXPANSION - IMPLEMENTATION SCHEDULE

PYXIS MEDSTATION EXPANSION - IMPLEMENTATION SCHEDULE PHASE 1 - Planning for MedStation Conversion Review Narcotic/Cerner/AMS usage and determine mins and maxs for all areas (drawer configurations) 11/01/07 Map medstations (assign meds to drawers and pockets

More information

This Chapter Contains:

This Chapter Contains: This Chapter Contains: State and Federal Laws Relating to Controlled Substances and Other Medications Drugs Used in Animal Shelters Acquiring Controlled Substances Record Keeping of Controlled Substances

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26)

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH20012-MGfa-35H* (01/26) H GENERAL ASSEMBLY OF NORTH CAROLINA SESSION HOUSE BILL DRH0-MGfa-H* (01/) H.B. Mar, HOUSE PRINCIPAL CLERK D Short Title: Strengthen Opioid Misuse Prevention (STOP)Act. (Public) Sponsors: Referred to:

More information

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation.

Pharmacy Law Disclosure Statement. Objectives 6/11/2016. I have no conflicts of interest to disclose related to this presentation. Pharmacy Law 2016 Ronda H. Lacey, J.D., M.S. Pharm Disclosure Statement I have no conflicts of interest to disclose related to this presentation. Objectives At the conclusion of this continuing education

More information

Prescribing and Dispensing Drugs

Prescribing and Dispensing Drugs STANDARDS & GUIDELINES Prescribing and Dispensing Drugs TABLE OF CONTENTS Standards and guidelines inform practitioners and the public of CDSBC s expectations for registrants. This document primarily contains

More information

Controlled Substances Program Procedures. UC Merced Environmental Health and Safety August 2015

Controlled Substances Program Procedures. UC Merced Environmental Health and Safety August 2015 Controlled Substances Program Procedures UC Merced Environmental Health and Safety August 2015 0 I. Introduction II. III. IV. Definitions Registrations Campus Authorization Requirements V. Training VI.

More information

PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998

PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 PHARMACY 543 PHARMACY LAWS & ETHICS MIDTERM EXAMINATION October 29, 1998 Questions 1 20 are multiple choice; please record answers on Side 2 of a Standard Answer Sheet, Form 1158. Follow the instructions

More information

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q)

Performance of North Carolina's System for Monitoring Prescription Drug Abuse. Session Law , Section 12F.16.(q) Performance of North Carolina's System for Monitoring Prescription Drug Abuse Session Law 2015-241, Section 12F.16.(q) Report to the Joint Legislative Oversight Committee on Health and Human Services and

More information

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION

NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION Chapter NEW MEXICO DEPARTMENT OF HEALTH Administrative Manual ADMINISTRATION EFFECTIVE: Policy REVISED: 4/13/9 draft NALOXONE DISTRIBUTION POLICY I. PURPOSE: This New Mexico Department of Health (NMDOH)

More information

Use of Controlled Substances in Research.

Use of Controlled Substances in Research. 3341-7-09 Use of Controlled Substances in Research. Applicability Faculty and staff who hold federal Drug Enforcement Administration (DEA) licenses to use controlled substances for research purposes. Responsible

More information

California. Prescribing and Dispensing Profile. Research current through November 2015.

California. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile California Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

Policy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult

Policy and Issuance Patient Age Group: ( ) N/A ( ) All Ages ( ) Newborns ( X) Pediatric ( X) Adult Applies To: Ambulatory Services Responsible Department: Ambulatory Admin Revised: 02/2018 Title: Controlled Substance Prescription Processing, Security Policy and Issuance Patient Age Group: ( ) N/A (

More information

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243

GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW HOUSE BILL 243 GENERAL ASSEMBLY OF NORTH CAROLINA SESSION 2017 SESSION LAW 2017-74 HOUSE BILL 243 AN ACT STRENGTHENING OPIOID MISUSE PREVENTION BY EXTENDING STANDING ORDERS FOR OPIOID ANTAGONIST TO COMMUNITY HEALTH GROUPS;

More information

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date:

CARD/MAIL/PRE-APPROVAL/PREFERRED RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: RIDER FOR PRESCRIPTION DRUG [INSURANCE] [Policy]holder: Group Policy No: Effective Date: CARD/MAIL/PRE-APPROVAL/PREFERRED The Prescription Drug Coverage under this Rider [replaces] [supplements] the Prescription

More information

SWGFAST Quality Assurance Guidelines for Latent Print Examiners

SWGFAST Quality Assurance Guidelines for Latent Print Examiners SWGFAST Quality Assurance Guidelines for Latent Print Examiners Friction ridge examinations are based on the following premises: The fundamentals of the science of friction ridge individualization (identification)

More information

Drug Diversion from the Healthcare Workplace A Multi-Victim Crime. Keith H. Berge MD

Drug Diversion from the Healthcare Workplace A Multi-Victim Crime. Keith H. Berge MD Drug Diversion from the Healthcare Workplace A Multi-Victim Crime Keith H. Berge MD Consultant in Anesthesiology- Mayo Clinic Rochester, MN Chair- Mayo Clinic Medication Diversion Prevention Committee

More information

Controlled Substances Program. For Academic Units

Controlled Substances Program. For Academic Units Brigham Young University Page 1 Provo, Utah Controlled Substances Program For Academic Units Last Revised: November 30, 2009 Brigham Young University Page 2 TABLE OF CONTENTS Section Title Page 1.0 Overview

More information

QUALITY ASSURANCE GUIDELINES FOR LATENT PRINT EXAMINERS

QUALITY ASSURANCE GUIDELINES FOR LATENT PRINT EXAMINERS QUALITY ASSURANCE GUIDELINES FOR LATENT PRINT EXAMINERS Preamble SWGFAST recognizes the importance and significance of establishing Quality Assurance protocols and procedures for friction ridge examination.

More information

247 CMR BOARD OF REGISTRATION IN PHARMACY

247 CMR BOARD OF REGISTRATION IN PHARMACY 247 CMR 18.00: NON-STERILE COMPOUNDING Section 18.01: Authority and Purpose 18.02: Non-Sterile Compounding Process 18.03: Non-Sterile Compounding Facility 18.04: Non-Sterile Compounding Equipment 18.05:

More information

Changes to the Eighth Edition

Changes to the Eighth Edition Pharmacy Practice and the Law, Eighth Edition Includes Navigate 2 Advantage Access By Richard R. Abood, BS Pharm, JD-Professor Emeritus Pharmacy Practice, Thomas J. Long School of Pharmacy and Health Sciences,

More information

9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment

9/3/2013. Presentation Objective. Prescription Drug Abuse Statistics Prescription Drug Abuse Statistics. Pharmaceutical Drugs and the Environment Presentation Objective Background - Why do we need a regulation for the disposal of controlled substances. Disposal of Controlled Substances DEA Notice of Proposed Rulemaking AHMP 2013 National Conference

More information

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program

Report to the Legislature: Unsolicited Reporting Criteria Established and Process Review MN Prescription Monitoring Program This document is made available electronically by the Minnesota Legislative Reference Library as part of an ongoing digital archiving project. http://www.leg.state.mn.us/lrl/lrl.asp Minnesota Board of

More information

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP

4/24/15. New Mexico s Prescription Monitoring Program. Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy. New Mexico and the PMP New Mexico s Carl Flansbaum, RPh. PMP Director New Mexico Board of Pharmacy New Mexico and the PMP In 2012, New Mexico had the 3 nd Highest Overdose Death Rate in Nation.! 492 Deaths or a rate of 23.6

More information

Controlled Substances: A survey of tools and resources required by hospital pharmacists

Controlled Substances: A survey of tools and resources required by hospital pharmacists Controlled Substances: A survey of tools and resources required by hospital pharmacists TABLE OF CONTENTS 2018. Canadian Society of Hospital Pharmacists About the survey 1 The Short and Snappy 1 What CSHP

More information

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion

AHLA. X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Fraud and Compliance Forum, October 2017. Click here to access audio. AHLA X. Federal Enforcement of Fraud and Abuse Involving Opioid Abuse and Diversion Michelle Bergholz Frazier Senior Vice President,

More information

Error Reduction Strategies for High-Alert Medications Kelly Besco, Pharm.D., FISMP, CPPS

Error Reduction Strategies for High-Alert Medications Kelly Besco, Pharm.D., FISMP, CPPS Error Reduction Strategies for High-Alert Medications Kelly Besco, Pharm.D., FISMP, CPPS Medication Safety Officer OhioHealth Pharmacy Services Conflict of Interest Disclosure Kelly Besco declares no conflicts

More information

View/Enter Patient Record. 3.1 CP-UC1-PS1 Refill Prescription (CASH)

View/Enter Patient Record. 3.1 CP-UC1-PS1 Refill Prescription (CASH) 3 CP-UC1 Dispense Prescription The community pharmacy use case group one (CP-UC1) contains workflows and activities that are focused on the dispensing of a medication to the patient. ID CP-UC1-PS1 CP-UC1-SS1

More information

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases

Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Challenges for U.S. Attorneys Offices (USAO) in Opioid Cases Overview On August 2, 2017, U.S. Attorney General Jeff Sessions announced a pilot program whereby a new federal data analysis program is being

More information

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain

Missouri Guidelines for the Use of Controlled Substances for the Treatment of Pain Substances for the Treatment of Pain Effective January 2007, the Board of Healing Arts appointed a Task Force to review the current statutes, rules and guidelines regarding the treatment of pain. This

More information

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition)

PART 1306 PRESCRIPTIONS. 21 CFR Ch. II ( Edition) 1305.16 1305.16 Special procedure for filling certain order forms. (a) The purchaser of carfentanil etorphine hydrochloride or diprenorphine shall submit copy 1 and 2 of the order form to the supplier

More information

Sample Drug Incident Report Form

Sample Drug Incident Report Form Sample Drug Incident Report Form Drug incident - patient safety report 1. As per Standard 1.9 of the Standards of Practice for Pharmacists and Pharmacy Technicians, each pharmacist and pharmacy technician

More information

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM

COLORADO PRESCRIPTION DRUG MONITORING PROGRAM COLORADO PRESCRIPTION DRUG MONITORING PROGRAM Harold Rogers Prescription Drug Monitoring Program West Regional Meeting Salt Lake City, Utah August 12 13, 2014 Tia Stakely, M.S. PDMP Administrator 2005

More information

HUMA RESOURCES POLICY

HUMA RESOURCES POLICY HUMA RESOURCES POLICY Title: Drug Free Workplace Policy No: 3.08 Originator: Human Resources Page: 1 of 7 Purpose To provide written notification to employees that Children s Medical Center of Dallas (Children

More information

PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH

PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH San Diego State University Environmental Health and Safety PROGRAM FOR THE USE OF CONTROLLED SUBSTANCES OR PRECURSOR/LIST CHEMICALS IN RESEARCH SUMMARY A number of substances or chemicals regulated by

More information

Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping

Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping Minnesota Board of Pharmacy Report to the Legislature: Impact of the Minnesota Prescription Monitoring Program on Doctor Shopping Prepared By: Dr. Katrina Howard, PMP Pharmacist Consultant October 31,

More information

Integrated Analytics Solutions. Your shortcut to performance excellence

Integrated Analytics Solutions. Your shortcut to performance excellence Integrated Analytics Solutions Your shortcut to performance excellence Integrated Analytics Solutions for Alaris System Your key to actionable infusion information Executive summary Below is a summary

More information

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015.

Tennessee. Prescribing and Dispensing Profile. Research current through November 2015. Prescribing and Dispensing Profile Tennessee Research current through November 2015. This project was supported by Grant No. G1599ONDCP03A, awarded by the Office of National Drug Control Policy. Points

More information

The Wisconsin Prescription Drug Monitoring Program

The Wisconsin Prescription Drug Monitoring Program The Wisconsin Prescription Drug Monitoring Program DHS 2018 WI Opioid Forum April 12, 2018 Learning Objectives 1. How the WI epdmp supports healthcare professionals in making informed prescribing, dispensing

More information

Technician Tutorial: Scheduled Drugs

Technician Tutorial: Scheduled Drugs (Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part

More information

SUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/

SUBJECT: Effective Date: Policy Number: Controlled Substance and Prescription Drugs 11/30/ Division of Research SUBJECT: Effective Date: Controlled Substance and Prescription Drugs 11/30/2018 Supersedes: Page Of 12/04/2015 04/25/2007 1 6 Responsible Authorities: Vice President, Research Institutional

More information

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin.

The Wisconsin Prescription Drug Monitoring Program. WI PDMP Timeline. PDMP Overview. What is a PDMP? PDMPs Across the Nation. Wisconsin. The Wisconsin Prescription Drug Monitoring Program Wisconsin Nurses Association Jail Health Care Conference May 21, 2018 WI PDMP Timeline PDMP Overview January 2013 WI PDMP operational April 2017 WI epdmp

More information

What is drug diversion?

What is drug diversion? Learning Objectives Identify the impact of drug diversion on patients and healthcare organizations Explain the common points of risks and methods of drug diversion in healthcare s controlled substance

More information

Human Resources All Personnel BP 4020 DRUG AND ALCOHOL-FREE WORKPLACE

Human Resources All Personnel BP 4020 DRUG AND ALCOHOL-FREE WORKPLACE BP 4020 DRUG AND ALCOHOL-FREE WORKPLACE The Governing Board believes that the maintenance of drug and alcohol-free workplaces is essential to school and district operations. No employee shall unlawfully

More information

UnitedHealthcare Community Plan of Iowa. Critical Incident Report (CIR) Form (Rev. 1/17) User Reference Guide

UnitedHealthcare Community Plan of Iowa. Critical Incident Report (CIR) Form (Rev. 1/17) User Reference Guide UnitedHealthcare Community Plan of Iowa Critical Incident Report (CIR) Form 470-4698 (Rev. 1/17) User Reference Guide User Reference Guide Critical Incident Report (CIR) Form 470-4698 (Rev. 1/17) Table

More information

Substance Abuse Policy. Substance Abuse Policy for Employees and Students

Substance Abuse Policy. Substance Abuse Policy for Employees and Students College Rules and Regulations 2.2008.1 Substance Abuse Policy Substance Abuse Policy for Employees and Students I. Substance Abuse Policy for Employees and Students A. Purpose The County College of Morris

More information

H 7816 S T A T E O F R H O D E I S L A N D

H 7816 S T A T E O F R H O D E I S L A N D LC00 01 -- H 1 S T A T E O F R H O D E I S L A N D IN GENERAL ASSEMBLY JANUARY SESSION, A.D. 01 A N A C T RELATING TO BUSINESSES AND PROFESSIONS - PHARMACIES Introduced By: Representatives Serpa, Canario,

More information

On December 27, 2017, the Lieutenant Governor signed into law several new requirements

On December 27, 2017, the Lieutenant Governor signed into law several new requirements OPIOID Alert MICHIGAN OSTEOPATHIC ASSOCIATION JANUARY 2018 On December 27, 2017, the Lieutenant Governor signed into law several new requirements aimed at combating the opioid epidemic. On the following

More information

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP)

April 26, New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) New Mexico Nurse Practitioner Council New Mexico Board of Pharmacy Prescription Monitoring Program (PMP) Peter Ryba, PharmD PMP Director

More information

NC General Statutes - Chapter 90 Article 5E 1

NC General Statutes - Chapter 90 Article 5E 1 Article 5E. North Carolina Controlled Substances Reporting System Act. 90-113.70. Short title. This Article shall be known and may be cited as the "North Carolina Controlled Substances Reporting System

More information

Standards, Education, Verification. Patient Focused Certification

Standards, Education, Verification. Patient Focused Certification Standards, Education, Verification Patient Focused Certification PFC Training helps you achieve quality standards. Staff Certification is now available online www.pfctraining.org jahan@safeaccessnow.org

More information

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update

4/26/2018. Bureau of Professional Licensing. MAPS Updates & Opportunities. MAPS Background. Registration. MAPS Update Bureau of Professional Licensing MAPS Updates & Opportunities April 28, 2018 Presented by Andrew Hudson, Manager Haley Winans, Analyst Drug Monitoring Section Bureau of Professional Licensing BPL-MAPS@Michigan.gov

More information

Antidepressants for treatment of depression.

Antidepressants for treatment of depression. JR3 340 1 of 9 PSYCHOTROPIC MEDICATIONS PURPOSE The use of psychotropic medication as part of a youth's comprehensive mental health treatment plan may be beneficial. The administration of psychotropic

More information

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program

Illinois Prescription Monitoring Program. Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Illinois Prescription Monitoring Program Sarah Pointer, Pharm D. Clinical Director of the Illinois Prescription Monitoring Program Agenda Provide an overview of the Illinois Prescription Monitoring Program

More information

Technical Assistance Guide No Recommended PDMP Reports to Support Licensing/Regulatory Boards and Law Enforcement Investigations

Technical Assistance Guide No Recommended PDMP Reports to Support Licensing/Regulatory Boards and Law Enforcement Investigations Technical Assistance Guide No. 02-14 Recommended PDMP Reports to Support Licensing/Regulatory Boards and Law Enforcement Investigations This project was supported by Grant No. 2011-PM-BX-K001 awarded by

More information

C. No employee shall report to work or remain on duty while having a detectable blood alcohol concentration.

C. No employee shall report to work or remain on duty while having a detectable blood alcohol concentration. 1 Series 3000 Personnel Section 3100 General Provisions Policy 3101 Drug Free Work Place File: 3101 3101.1 STATEMENT OF PURPOSE: The WV Board of Education and the Harrison County Board of Education recognize

More information

Prescription Drug Monitoring Program (PDMP)

Prescription Drug Monitoring Program (PDMP) Prescription Drug Monitoring Program (PDMP) District of Columbia Information contained in this presentation is accurate as of September 2017 Meet the Speaker Tadessa Harper-Nichols Program Specialist Pharmaceutical

More information

Health Officer Order

Health Officer Order September 24, 2018 Health Officer Order Mandatory Influenza Vaccination or Masking of Kern County Health Care Workers During Influenza Season UPDATE Dear Kern County Health Care Provider: In order to lower

More information

Strategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures

Strategies to Prevent Pharmaceutical Waste: Modifying Co-Pay Structures Modifying Co-Pay Structures Extended producer responsibility (EPR) is a policy approach in which the producer s responsibility for their product extends to the post-consumer management of that product

More information

SONOMA COUNTY LAW ENFORCEMENT CHIEFS ASSOCIATION

SONOMA COUNTY LAW ENFORCEMENT CHIEFS ASSOCIATION SONOMA COUNTY LAW ENFORCEMENT CHIEFS ASSOCIATION PROTOCOL: 97-3 ADOPTED: 08/08/1997 REVISED: 02/10/2006 05/03/2007 SUBJECT: PURPOSE: MEDICAL MARIJUANA To provide for consistency among law enforcement agencies

More information

Safe Management of Controlled Drugs

Safe Management of Controlled Drugs Definitions Safe Management of Controlled Drugs Controlled drugs Any drug listed in any schedule of the Misuse of Drugs Act refer to Appendix 1 Introduction This protocol describes the procedures in place

More information

What Do IACP Members Think?

What Do IACP Members Think? What Do IACP Members Think? Results of a National Survey of Compounding Practitioners February 27, 2013 Final Summary Results What Do Compounders Think? National Survey of 2,857 pharmacists and technicians

More information

Interpret Converting oral communication from one language to another. Translate Converting written communication from one language to another.

Interpret Converting oral communication from one language to another. Translate Converting written communication from one language to another. Page 1 of 6 PURPOSE: To define the manner by which Sierra View District Hospital (SVDH) will accommodate the interpretive needs of the patients and to delineate the mechanisms used to ensure that potential

More information

ARKANSAS DEPARTMENT OF HEALTH

ARKANSAS DEPARTMENT OF HEALTH ARKANSAS DEPARTMENT OF HEALTH RULES AND REGULATIONS PERTAINING TO CONTROLLED SUBSTANCES (July 26, 2001) I, Jerry Jones, P.D., Director of Pharmacy Services and Drug Control for the Arkansas Department

More information

ADMINISTRATION OF NALOXONE HCI REVISED: 10/17

ADMINISTRATION OF NALOXONE HCI REVISED: 10/17 POLICY 513 ADMINISTRATION OF NALOXONE HCI REVISED: 10/17 RELATED POLICIES: CFA STANDARDS: 14.14 REVIEWED: AS NEEDED A. PURPOSE The purpose of this policy is to establish guidelines and procedures governing

More information

C U S T O M E R D R I V E N. B U S I N E S S M I N D E D.

C U S T O M E R D R I V E N. B U S I N E S S M I N D E D. MAPS Update May 4, 2018 Presented by Kim Gaedeke, Acting Deputy Director Department of Licensing and Regulatory Affairs Andrew Hudson, Manager Drug Monitoring Section BPL-MAPS@Michigan.gov 517-373-1737

More information

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS

RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS RULES OF THE TENNESSEE BOARD OF PHARMACY CHAPTER 1140-17 DRUG DONATION REPOSITORY PROGRAM TABLE OF CONTENTS 1140-17-.01 Definitions 1140-17-.02 Purpose 1140-17-.03 Eligibility Criteria for Program Participation

More information

Secure Medicine Return Regulations King County, Washington

Secure Medicine Return Regulations King County, Washington Secure Medicine Return Regulations King County, Washington Board of Health Chapter 11.50 New law to create a sustainably financed, county-wide secure medicine return system SMR-090413 King County Passes

More information

Drug Incident Report Form

Drug Incident Report Form Drug Incident Report Form Drug incident - patient safety report 1. As per Standard 1.9 of the Standards of Practice for Pharmacists and Pharmacy Technicians, each pharmacist and pharmacy technician must

More information

SCHEDULE 2 THE SERVICES

SCHEDULE 2 THE SERVICES SCHEDULE 2 THE SERVICES A. Service Specifications Mandatory headings 1 4: mandatory but detail for local determination and agreement Optional headings 5-7: optional to use, detail for local determination

More information

Arkansas Pharmacy Law Update. John Clay Kirtley, Pharm.D. Assistant Director Arkansas State Board of Pharmacy

Arkansas Pharmacy Law Update. John Clay Kirtley, Pharm.D. Assistant Director Arkansas State Board of Pharmacy Arkansas Pharmacy Law Update John Clay Kirtley, Pharm.D. Assistant Director Arkansas State Board of Pharmacy Objectives Analyze recent changes in Pharmacy regulations in Arkansas Discuss the reasoning

More information

Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009

Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Safe Medication Disposal A white position paper Pennsylvania Pharmacists Association February 8, 2009 Background and Situation Analysis: Consumers are rightly confused about what to do with their unwanted

More information

Refilling a Prescription with No Refills Remaining

Refilling a Prescription with No Refills Remaining ................................................................................................... Refilling a Prescription with No Refills Remaining Pharmacy Technology Solutions May, 2013 Refilling

More information

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable

Mandatory PDMP Use PDMP Use STATE Prescriber Dispenser Conditions, if applicable Arizona Amends worker s compensation statute to require physicians to request PMP information within two (2) business days of writing or dispensing prescriptions for at least a 30 day supply of an opioid

More information

DELTA DENTAL PREMIER

DELTA DENTAL PREMIER DELTA DENTAL PREMIER PARTICIPATING DENTIST AGREEMENT THIS AGREEMENT made and entered into this day of, 20 by and between Colorado Dental Service, Inc. d/b/a Delta Dental of Colorado, as first party, hereinafter

More information

Drug and Alcohol Testing Policy for Positions Requiring COMMERCIAL DRIVER S LICENSE (CDL)

Drug and Alcohol Testing Policy for Positions Requiring COMMERCIAL DRIVER S LICENSE (CDL) Drug and Alcohol Testing Policy for Positions Requiring COMMERCIAL DRIVER S LICENSE (CDL) City of Urbandale, Iowa City Council Approved October 1, 2013 Scope: This policy is written to comply with the

More information

ASPMN Conference Baltimore, Maryland

ASPMN Conference Baltimore, Maryland ASPMN Conference Baltimore, Maryland Prescribing Controlled Substances Managing Risk and Optimizing Outcomes September 13, 2012 Tracey Fremd, NP Tracey Fremd Consulting, Inc. Most Common Uses for Controlled

More information

Key Findings and Recommendations from the

Key Findings and Recommendations from the June 2014 Improving Community Health Through Policy Research Key Findings and Recommendations from the 2013 IPLA INSPECT Knowledge and Use Survey 2014 Center for Health Policy (14-H54) IU Richard M Fairbanks

More information

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director

BOARD OF PHARMACY- REGULATORY UPDATE. Kimberly Grinston, J.D., Executive Director BOARD OF PHARMACY- REGULATORY UPDATE Kimberly Grinston, J.D., Executive Director Disclosure and Conflict of Interest I declare no conflicts of interest, real or apparent, and no financial interest in any

More information

Center for Family Health Policy

Center for Family Health Policy Subject: Vaccine Management and Administration (Immunization) BOARD APPROVED: 7/30/96 REVISION APPROVED: 05/03/05, 04/08/08, 04/07/09, 04/12/11 Purpose: To ensure safe and appropriate storage, handling

More information

Student Affairs Approved By: Richard R. Rush Effective Date: 2/26/07 President Page 1 of 6. Policy on Alcohol at CSUCI. Superseded

Student Affairs Approved By: Richard R. Rush Effective Date: 2/26/07 President Page 1 of 6. Policy on Alcohol at CSUCI. Superseded President Page 1 of 6 PURPOSE: The University Alcohol Policy relates to all members of the campus community with the exception of tenants leasing space in the academic campus with pre-existing agreements

More information

LUNCH AND LEARN. January 8, CE Activity Information & Accreditation

LUNCH AND LEARN. January 8, CE Activity Information & Accreditation LUNCH AND LEARN Pharmacy Law: The Ins and Outs of Controlled Substances January 8, 2016 Featured Speaker: Joseph J. Bogdan, Pharm.D., R.Ph., J.D. Pharmacist Attorney Lisle, Illinois 1 CE Activity Information

More information

Prescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017

Prescription Drug Monitoring Program (PDMP) Delaware. Information contained in this presentation is accurate as of November 2017 Prescription Drug Monitoring Program (PDMP) Delaware Information contained in this presentation is accurate as of November 2017 Dr. Michael C. Dejos, PharmD, BCPS, LSSBB 2 Acknowledgements Christian Ruffin,

More information

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic

Teaching Objectives Describe the balance a that must be sought in the treatment of pain and the prevention of drug diversion. Discuss regulatory polic Preventing Controlled Substance Diversion David B. Brushwood, R.Ph.,., J.D. Professor of Pharmaceutical Outcomes & Policy The University of Florida Teaching Objectives Describe the balance a that must

More information